Free tool
FAERS Monitor: Fludeoxyglucose F18
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021870 or its brand name (Fludeoxyglucose F18, Fludeoxyglucose F-18). Reports on generic versions are filed under their own applications.
Reports
274
Serious
204
74% of reports
Hospitalization
111
Death reported
43
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome24
- drug ineffective17
- nausea16
- off label use15
- hypotension13
- neutropenia13
- platelet count decreased12
- pyrexia12
- rash maculo-papular11
- bone marrow failure10
- death10
- wrong product administered10
- covid-199
- dyspnoea9
- febrile neutropenia9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2009 | 9 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 14 |
| 2013 | 6 |
| 2016 | 3 |
| 2017 | 9 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 13 |
| 2021 | 18 |
| 2022 | 42 |
| 2023 | 51 |
| 2024 | 24 |
| 2025 | 36 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,885 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wrong product administeredSignal | 10 | 113.8 | 61.9 | 1,007 |
| cytokine release syndromeSignal | 24 | 92.0 | 62.7 | 2,069 |
| rash maculo-papularSignal | 11 | 38.0 | 21.3 | 360 |
| bone marrow failureSignal | 10 | 37.8 | 20.6 | 323 |
| febrile neutropeniaSignal | 9 | 10.4 | 5.5 | 68 |
| platelet count decreasedSignal | 12 | 8.6 | 5.0 | 74 |
| neutropeniaSignal | 13 | 7.3 | 4.3 | 65 |
| hypotensionSignal | 13 | 5.0 | 2.9 | 38 |
| covid-19Signal | 9 | 3.9 | 2.1 | 17 |
| pyrexiaSignal | 12 | 2.7 | 1.5 | 11 |
| nausea | 16 | 1.6 | 1.0 | 3 |
| off label use | 15 | 1.3 | 0.8 | 1 |
| dyspnoea | 9 | 1.2 | 0.6 | 0 |
| drug ineffective | 17 | 1.0 | 0.6 | 0 |
| death | 10 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.